FDA Accelerated Approval of Genglycos (pariglasgene brecaparvovec-opnr) for GSDIa
The FDA issued an accelerated approval for Genglycos (pariglasgene brecaparvovec-opnr), a one-time AAV8-based gene therapy, for patients aged 8 years and o…
Impact analysis · 55/100 · AI-assisted priority
This score prioritizes research; it does not predict an outcome. Method and limitations.
What happened
The FDA issued an accelerated approval for Genglycos (pariglasgene brecaparvovec-opnr), a one-time AAV8-based gene therapy, for patients aged 8 years and older with glycogen storage disease type Ia as an adjunct to nutritional management.
Quantitative evidence
- 31% mean reduction in daily cornstarch intake versus placebo
- one cornstarch dose per day mean reduction in Genglycos group versus placebo
- long-term clinical benefit to be confirmed in post-approval trials
- magnitude of effect on hypoglycemia frequency
Affected entities
Analysis
The following contextual analysis is AI-assisted and separated from the reported primary-source record above.
Scientific context
This is the first approved gene therapy targeting the underlying G6PC deficiency in GSDIa, using an AAV8 vector to deliver a functional gene to the liver, showing surrogate endpoint efficacy in cornstarch reduction.
Market context
Ultragenyx, the sponsor named in the approval, now holds the first–ever approved treatment for GSDIa, potentially displacing intensive dietary therapy.
Legal and regulatory context
This is an accelerated approval; confirmatory clinical trials are required to verify long-term benefit under FDA postmarketing requirements.
Sources
For informational use only. Verify decisions against the linked regulator or primary source.
Evidence & limits
Source: Open the source record
- Record identifier
- ecfd0898a5ba4d24e16e677eb8ca51a1deec0b73c505e9551f4e539875ee3c0c
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- 2026-08-20T130911Z
What it supports. The linked authority’s action, within the product, indication, jurisdiction, and procedural stage stated in that record.
Limits. A committee opinion, draft, or announcement does not by itself establish final authorization. The summary and contextual analysis are AI-assisted; a source link does not establish human review.
Connection basis. Related profiles are normalized name mentions in article text. A mention does not establish a legal relationship.